Category Archives: Cost of Clinical Trials

Risk-based monitoring (RBM) is a method that uses risk algorithms to assess the right level of clinical trials monitoring. Food and Drug Administration (FDA) and European Medicines Agency (EMA) currently encourage this approach. RBM focuses on improving quality of the … Continue reading →

It is well known in the clinical trial industry that the start-up phase of clinical studies can be very challenging. It is at this stage of development that clinical trials must lay the groundwork for success, and good intelligence gathering … Continue reading →

In previous posts I’ve discussed the barriers to successful patient recruitment in the establishment of clinical trials. Whilst this is considered to be one of the major causes of delay in the clinical trials set-up process, it is by no … Continue reading →

The rising cost of clinical trials is unequivocal, as we all know. The price increase has outstripped inflation, almost continuously, since clinical trials were first employed to support pharmaceutical development. To outline the extent, R&D supporting the average FDA drug … Continue reading →

There’s no doubt about it, a strong investment climate in BioPharma, biotech and other Life Science industries means more money for clinical trials. Here at Clinical Accelerator we keep a keen eye on market trends, and this August new data … Continue reading →

As I cast my eyes over the news that everolimus (Afinitor) failed to slip smoothly through Phase III trials for treatment of advanced liver cancer – as it has for advanced kidney cancer, certain cases of advanced breast cancer and specific … Continue reading →

Let’s look at the greatest failures of last year’s clinical trials and consider where better processes could reduce the chances of defeat or of how much is written-down. The ten clinical trials conducted in 2013 that resulted in most financial … Continue reading →

The substantial cost of clinical trials will be reduced a fraction after implementation of the EU’s updated regulations governing clinical trials. The Commission estimates an annual saving of €800 million (1,088 million euros, £643 million). This is about 60% of … Continue reading →